Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Videos|July 25, 2023
The Best Referrals to PM&R for Back Pain are the Early Ones, says AAPM&R President-Elect DJ Kennedy, MD
Author(s)Grace Halsey
Advertisement
There is no precise formula for calculating when a patient with back pain is a candidate for referral to physical medicine and rehabilitation but there is a set of basic principles that physiatrist DJ Kennedy, MD, says accounts for the majority of patients referred to him by primary care clinicians.
In a recent conversation with Patient Care, Kennedy, president-elect of the American Academy of Physical Medicine and Rehabilitation, outlined those and discussed the essential synergy between PCPs and PM&R.
DJ Kennedy, MD, is president-elect of the American Academy of Physical Medicine and Rehabilitation and professor in and chair of physical medicine and rehabilitation at Vanderbilt University Medical Center, in Nashville, TN, where his practice focuses on nonoperative and interventional spine care. He has served as a senior editor for the journal PM&R, on the editorial board for Pain Medicine, and as a deputy editor for The Spine Journal. Kennedy also is current president of the Spine Intervention Society.
Advertisement
Related to this article
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Post hoc LUCENT-2 and VIVID-1 analyses show more mirikizumab-treated patients reached steroid-free composite remission in UC and Crohn disease at 1 year.
The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
Advertisement
Advertisement
Trending on Patient Care Online
1
Who Should Get a CGM? Expanding the Primary Care Candidate Pool
2
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
3
Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease
4
Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
5